What a legitimate online GLP-1 evaluation looks like
A legitimate telehealth GLP-1 evaluation involves at minimum three steps: a structured health intake, clinical review by a licensed provider, and a decision on whether to prescribe. That last step is the critical one. Legitimate providers decline patients who do not meet clinical criteria, and no medication should ship before a clinician has individually reviewed the case.
The health intake typically collects current weight, height, blood pressure history, medical diagnoses, current medications, and personal and family medical history. Some platforms use an asynchronous questionnaire reviewed by a clinician within 24 to 48 hours; others schedule a short video or phone visit. Either format can satisfy telehealth prescribing requirements, but the provider review is not optional. According to a July 2026 research letter published in JAMA, nearly 20% of adults who take a GLP-1 receptor agonist now obtain their prescription online, and the depth of clinical engagement varies widely across platforms.
After the clinical review, a licensed prescriber issues a prescription to a licensed pharmacy if the patient qualifies. For FDA-approved brand medications, this is a standard pharmacy prescription. For compounded formulations, the prescription goes to a compounding pharmacy, which ships directly to the patient. In both cases, a valid prescription from a licensed provider is legally required. Any seller that ships GLP-1 injections without a prescription is operating outside U.S. law.
Who typically qualifies: the BMI and comorbidity criteria
The eligibility benchmarks used by most telehealth providers mirror the indications on the FDA prescribing label for weight-management GLP-1 drugs. Wegovy (semaglutide 2.4 mg) is indicated for adults with a body mass index (BMI) of 30 kg/m2 or higher (obesity), or adults with a BMI of 27 kg/m2 or higher (overweight) who also have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Zepbound (tirzepatide) carries the same BMI thresholds, with qualifying comorbidities that also include obstructive sleep apnea and cardiovascular disease. For someone who is 5 feet 6 inches tall, a BMI of 30 corresponds to roughly 186 pounds. That same person meets the 27 BMI threshold at about 167 pounds, provided a qualifying condition is documented.
These criteria apply to FDA-approved brand medications. Providers who prescribe compounded semaglutide or compounded tirzepatide typically use the same thresholds as a clinical reference, but patients should confirm this with the specific platform. It is important to note that compounded semaglutide and compounded tirzepatide are not FDA-approved, and the FDA has not evaluated them for safety, efficacy, or quality in the same process applied to brand medications.
Mounjaro (tirzepatide for type 2 diabetes) and Ozempic (semaglutide 0.5 to 2 mg for type 2 diabetes) are separate FDA-approved products indicated for glycemic control in adults with type 2 diabetes; their eligibility criteria differ from the weight-management labels. A licensed provider can discuss whether those medications are appropriate in a given clinical situation.
Medical history that can disqualify or requires extra caution
Certain medical histories are absolute contraindications to GLP-1 receptor agonists. The Wegovy prescribing label lists a personal or family history of medullary thyroid carcinoma (MTC), or a personal diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as absolute contraindications. Animal studies in rodents showed that semaglutide caused thyroid C-cell tumors; whether this risk translates to humans is not yet established, but the boxed warning on the Wegovy label means every provider must screen for this history before prescribing.
Pregnancy is a situation in which GLP-1 medications are not recommended. Because weight loss during pregnancy is not a clinical goal and animal data suggest potential fetal risks, providers typically decline to prescribe. Most clinical guidelines recommend stopping GLP-1 medications at least two months before a planned pregnancy.
A history of acute pancreatitis calls for careful clinical judgment. The Wegovy label notes that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been observed in patients treated with GLP-1 receptor agonists. The label states that the drug should be discontinued promptly if pancreatitis is suspected and should not be restarted if pancreatitis is confirmed. Patients with a prior episode should discuss risks and benefits in detail with a clinician before starting.
Additional situations that warrant clinical discussion include a history of severe gastrointestinal disease, gastroparesis, serious hypersensitivity reactions to semaglutide or tirzepatide excipients, diabetic retinopathy requiring active management, eating disorders, and certain kidney conditions. A thorough telehealth platform screens for all of these during intake rather than rushing through to checkout.
What the health intake form actually covers
A thorough intake form does more than confirm BMI. It gathers the clinical information needed for a safe prescribing decision. Patients should expect these sections:
- Current weight and height, used to calculate BMI and confirm eligibility thresholds.
- Active medical diagnoses, including hypertension, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease. These matter both as qualifying conditions and as factors that affect medication choice and monitoring.
- Current medications, including oral contraceptives, thyroid medications, insulin or sulfonylureas, and supplements. Some drugs interact with GLP-1 receptor agonists or complicate dose titration.
- Personal and family history of thyroid cancer, specifically medullary thyroid carcinoma or MEN 2 syndrome.
- History of pancreatitis, gallbladder disease, kidney disease, or eating disorders.
- Pregnancy status and reproductive plans.
- Recent laboratory work, such as HbA1c, a basic metabolic panel, or a lipid panel, if available.
Not every platform requires labs before issuing a first prescription, but those that do are meeting a higher standard of care. If an intake form asks no questions about medical history and offers a prescription in under five minutes with no clinical review, that pattern is a red flag rather than a sign of efficiency.
FDA-approved brand medications vs. compounded GLP-1 options
Two categories of GLP-1 medication are available through online prescribers today: FDA-approved brand drugs and compounded formulations. Understanding the distinction matters before committing to a provider.
FDA-approved brand medications include Wegovy (semaglutide 2.4 mg for weight management, Novo Nordisk), Ozempic (semaglutide for type 2 diabetes, Novo Nordisk), Zepbound (tirzepatide for weight management, Eli Lilly), Mounjaro (tirzepatide for type 2 diabetes, Eli Lilly), and the oral semaglutide tablet Rybelsus (for type 2 diabetes). These drugs were evaluated by the FDA for safety, efficacy, and manufacturing quality before receiving approval. Their indications, dosing schedules, and safety information are specified in FDA-reviewed labeling.
In the STEP 1 trial, participants using FDA-approved Wegovy (semaglutide 2.4 mg) lost an average of 14.9% of body weight over 68 weeks (Wilding et al., NEJM 2021). In the SURMOUNT-1 trial, participants using FDA-approved Zepbound (tirzepatide 15 mg) lost an average of 22.5% of body weight over 72 weeks (Jastreboff et al., NEJM 2022). These two trials had different designs, patient populations, durations, and background lifestyle interventions; the percentage figures are not directly comparable to each other. These results belong to those specific FDA-approved drugs studied in those trials. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials; those trial outcomes cannot be attributed to compounded formulations.
Compounded formulations are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Both are subject to regulatory oversight, but neither category is the same as an FDA-approved drug. "FDA-registered" describes a facility registration; it does not mean the compounded product itself has been reviewed or approved by the FDA.
Brand vs. compounded GLP-1: a side-by-side overview
The table below compares the two routes across key factors. Neither row is uniformly superior; the right choice depends on insurance coverage, clinical eligibility, and what a licensed provider recommends.
| Factor | FDA-approved brand medication | Compounded formulation |
|---|---|---|
| FDA review of safety and efficacy | Yes, before approval | No; not FDA-approved |
| Manufacturing oversight | FDA-inspected; strict CGMP standards | 503B: FDA-registered facility; 503A: state-licensed pharmacy |
| Prescription required | Yes | Yes |
| Typical dosage form | Pre-filled auto-injector pen or tablet | Typically a multi-dose vial drawn with a syringe |
| Approximate monthly cash-pay cost (no insurance) | $900 to $1,400 without a manufacturer savings program | $100 to $400 depending on dose and provider |
| Insurance coverage | Variable; prior authorization typically required for weight management | Generally not covered by insurance |
| Clinical trial data on the specific formulation | Yes (STEP trials for semaglutide; SURMOUNT trials for tirzepatide) | No equivalent trials on compounded formulations |
Red flags that signal an illegitimate seller
The FDA and FTC have both taken enforcement action against online GLP-1 sellers operating outside legal boundaries. The FDA issued warning letters to 30 telehealth companies in February 2026 for illegal marketing of compounded GLP-1 drugs. Separately, the FDA launched a "green list" import alert in 2026 to stop GLP-1 active pharmaceutical ingredients from unverified foreign sources from reaching patients. The FDA has also documented products bearing labels with pharmacy names that do not exist or that falsely claim affiliation with a licensed pharmacy.
Watch for these specific warning signs:
- No prescription required. Any seller offering GLP-1 injections without requiring a valid prescription is violating federal law. This is the clearest possible red flag.
- No licensed provider review. Checking boxes on a form with no subsequent clinician review is not a medical consultation. A provider must individually assess each patient before prescribing.
- No pharmacy identified. Every legitimate prescription must be filled by a named, licensed pharmacy. If the dispensing pharmacy is unnamed, unverifiable, or located outside the United States, that is a serious concern.
- Cryptocurrency or wire transfer as the only payment method. Legitimate healthcare providers accept standard payment. Crypto-only payment strongly suggests a fraudulent operation.
- Claims that a compounded product is FDA-approved, or that it produces the same results as a brand drug. These claims are prohibited by the FDA for compounded products and have been cited in multiple enforcement actions.
- No mechanism to reach a provider after receiving medication. The FDA has specifically noted that patients should have access to a licensed clinician to answer questions once treatment begins.
- Prices that are far below the market range for compounded GLP-1s with no explanation. Unusually low prices may indicate substandard sourcing or counterfeit ingredients.
Patients can verify that a 503B outsourcing facility is registered with the FDA by searching the FDA outsourcing facility database at fda.gov.
Questions to ask a provider before paying
Before completing a purchase or subscription with any online GLP-1 provider, these questions help assess whether the platform meets a reasonable standard of care:
- Which licensed pharmacy will fill my prescription? Ask for the pharmacy name, state license number, and whether it is a 503A pharmacy or a 503B outsourcing facility. A reputable provider answers this without hesitation.
- Who will review my health intake, and what are their credentials? Ask for the prescribing clinician's license type, state of licensure, and medical specialty. Board certification in obesity medicine (DABOM) or endocrinology is a strong credential for GLP-1 prescribing.
- What happens if I have a side effect or a medical question after I start? A reputable provider offers a defined pathway for clinical follow-up, not just a generic support email.
- Is this medication FDA-approved, or is it a compounded formulation? Either can be legitimate, but the regulatory differences are real and the provider should explain them clearly rather than obscuring them.
- What is included in the total price? Ask specifically whether the medication, laboratory work, and provider visits are bundled or billed separately. The FTC's 2025 final order against NextMed cited the company specifically for advertising plan prices that excluded drug and lab costs.
- How is care escalated if I need it? Telehealth platforms should have a clear protocol for patients who develop serious side effects or whose health changes significantly after starting treatment.
What happens after a provider approves the prescription
Once a provider approves a prescription, the next steps depend on the medication category. For FDA-approved brand medications, the prescription is sent to a retail or mail-order pharmacy. For compounded formulations through telehealth platforms, the prescription typically goes directly to the partnered compounding pharmacy, which ships to the patient, often with supplies such as syringes and alcohol swabs.
Most GLP-1 treatment plans follow a dose escalation schedule designed to reduce early gastrointestinal side effects. Wegovy, for example, begins at 0.25 mg weekly and titrates over approximately 16 weeks to the 2.4 mg maintenance dose. Zepbound starts at 2.5 mg and increases every four weeks. Starting low and going slow is the clinical standard, not a workaround.
Follow-up with a provider matters throughout treatment, not only at the start. Weight, blood pressure, and any new symptoms should be monitored on a regular schedule. If circumstances change (a new pregnancy attempt, a new prescription drug, significant unexplained symptoms, or a change in a qualifying condition), the prescribing clinician should be informed promptly. Platforms that build in at least quarterly check-ins are providing a more complete model of care than those that issue a prescription and go silent.
Because these medications address chronic conditions, the relationship with the prescribing provider should be durable, not transactional. A clinician who knows the full medical history is better positioned to advise on dose adjustments, plateaus, and the question many patients eventually face: whether to continue treatment long-term. See what happens when you stop taking a GLP-1 for what the research shows about weight trajectories after stopping.
Making a safe and informed choice
The online GLP-1 market ranges from clinically rigorous, responsible platforms to sellers with minimal medical oversight. The existence of legitimate options does not mean all options are legitimate. The 2026 JAMA research letter reinforced that wide variation exists, with some telehealth sites offering prescriptions with very little clinical engagement.
The safest approach is to treat an online GLP-1 consultation the way any clinical decision deserves to be treated: look for named and credentialed providers, a clearly identified dispensing pharmacy, transparent total pricing, and a defined pathway for follow-up care. A valid prescription and a named licensed pharmacy represent the baseline minimum, not an optional extra.
Starting, stopping, or changing any medication, including GLP-1 receptor agonists, should happen in coordination with a clinician who knows the full medical history. The goal is not only a prescription but a care relationship that makes the treatment safe and appropriate over time.